Agents and method for treating inflammation-related conditions and diseases

Gene-modified, inflammation-specific monocytes suitable for treating one or more than one inflammation-related condition or disease;

• the gene-modified, inflammation-specific monocytes comprising:
• a) a 1-alpha-hydroxylase gene that produces functional 1-alpha-hydroxylase when the monocytes transdifferentiate into gene-modified, inflammation-specific macrophages;
• and
• b) a macrophage-specific promoter that limits expression of the 1-alpha-hydroxylase gene until the gene-modified, inflammation-specific monocytes transdifferentiate into gene-modified, inflammation-specific macrophages, where the promoter is functional under conditions of inflammation.

Gene-modified, inflammation-specific macrophages suitable for treating one or more than one inflammation-related condition or disease;

• the gene-modified, inflammation-specific macrophages comprising:
• a) a 1-alpha-hydroxylase gene that produces functional 1-alpha-hydroxylase;
• and
• b) a growth factor gene that produces functional growth factor.

Gene-modified, inflammation-specific macrophages suitable for treating one or more than one inflammation-related condition or disease;

• the gene-modified, inflammation-specific macrophages comprising:
• a) a 1-alpha-hydroxylase gene that produces functional 1-alpha-hydroxylase;
• and
• b) a macrophage-specific promoter that limits expression of the 1-alpha-hydroxylase gene until the gene-modified, inflammation-specific macrophages transdifferentiate from gene-modified, inflammation-specific monocytes, where the promoter in functional under conditions of inflammation.